PAVEL SUMAZIN to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications PAVEL SUMAZIN has written about Xenograft Model Antitumor Assays.
Connection Strength
0.195
-
Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021 06 28; 12(1):4006.
Score: 0.038
-
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 02 03; 11(1):2967.
Score: 0.037
-
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227.
Score: 0.034
-
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018 03 27; 20(4):506-518.
Score: 0.030
-
A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma. Sci Rep. 2017 12 19; 7(1):17751.
Score: 0.030
-
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J Hepatol. 2016 08; 65(2):325-33.
Score: 0.026